Active substanceVancomycinVancomycin
Similar drugsTo uncover
  • Vancomobol®
    lyophilizate d / infusion 
    PREBAND PFC, LLC     Russia
  • Vancomycin
    powder d / infusion 
    KRASFARMA, JSC     Russia
  • Vancomycin
    powder d / infusion 
    FARMGID CJSC     Russia
  • Vancomycin
    lyophilizate inwards d / infusion 
  • Vancomycin
    lyophilizate inwards d / infusion 
    KRASFARMA, JSC     Russia
  • Vancomycin J
    lyophilizate d / infusion 
    JODAS EKSPOIM, LLC     Russia
  • Vancomycin-Teva
    lyophilizate d / infusion 
  • Vancoros®
    lyophilizate d / infusion 
    SYNTHESIS, OJSC     Russia
  • Vancocin®
    lyophilizate d / infusion 
    Eli Lilly East SA     Switzerland
  • Vero-Vancomycin
    lyophilizate d / infusion 
    VEROPHARM SA     Russia
  • Edicyin®
    lyophilizate d / infusion 
    Lek dd     Slovenia
  • Dosage form: & nbsplyophilizate for solution for infusion and oral administration
    Composition:

    Active substance: vancomycin hydrochloride 0.513 g; 1,026 g in terms of vancomycin - 0.5 g; 1.0 g.

    Description:Powder or porous mass from white to white with a pinkish or light brown hue.
    Pharmacotherapeutic group:Antibiotic glycopeptide
    ATX: & nbsp

    J.01.X.A.01   Vancomycin

    J.01.X.A   Antibiotics of the glycopeptide structure

    Pharmacodynamics:Vancomycin is a tricyclic glycopeptide antibiotic, produced Amycolatopsis orientalis. The bactericidal action of vancomycin is manifested in the inhibition of bacterial cell wall biosynthesis,is able to change the permeability of the bacterial cell membrane and the synthesis of ribonucleic acid (RNA). It blocks the synthesis of the bacterial cell wall in a region different from that of penicillins and cephalosporins (not competing with them for binding sites), strongly binding to the O-alanyl-O-alanine residues of the peptidoglycan subunits (located on the outer surface of the cytoplasmic membrane) the main component of the cell wall, which leads to cell lysis.

    It shows bactericidal action against many Gram-positive bacteria and bacteriostatic action against Enterococcus spp. Bactericidal effect on Enterococcus spp. is achieved by the combined use of vancomycin and aminoglycosides. Cross-resistance between vancomycin and antibiotics of other classes is absent.

    Active with respect to Gram-positive microorganisms: Staphylococcus aureus, Staphylococcus haemolyticus, Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), Streptococcus spp. (Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae and others, including penicillin-resistant strains), Enterococcus spp. (at t.h. Enterococcus faecalis), Clostridium spp., Propionibacterium acnes, Actinomyces spp., some strains Lactobacillus spp., Rhodococcus spp., Corynebacterium spp., Listeria monocytogenes, Bacillus spp.

    In vitro some isolated strains Enterococcus spp. and Staphylococcus spp. may exhibit resistance to vancomycin.

    In combination with aminoglycosides, synergy is observed in vitro for many strains Staphylococcus aureus, streptococcal group D, not belonging to enterococci, Enterococcus spp., Streptococcus groups viridans. In combination with gentamycin, tobramycin, rifampicin, imipenem, synergy is observed with respect to Staphylococcus aureus. In some cases, with the combination of vancomycin and rifampicin, antagonism of the action against strains Staphylococcus spp., this combination of drugs also shows a synergistic effect on some strains Streptococcus spp.

    Vancomycin is inactive in vitro in a relationship Gram-negative microorganisms, mycobacteria and fungi.

    Optimum action - at pH 8, with a decrease in pH to 6 the effect is sharply reduced.

    The development of resistance of staphylococci during the treatment is very rare. The value of the minimum inhibitory concentration (MIC) for most antibiotic-sensitive microorganisms is less than 5 μg / ml, the MIC value for vancomycin-resistant strains Staphylococcus aureus reaches 10-20 mg / l.

    When used internally has minimal systemic effect, acts locally on the sensitive microflora in the gastrointestinal tract (GIT) (Staphylococcus aureus, Clostridium difficile).

    Pharmacokinetics:

    Suction. After oral administration, it is absorbed in minimal amounts. Absorption of the drug is slightly higher with inflammation of the intestinal mucosa, in such patients, after taking 0.5 g of the drug every 6 hours, the maximum concentration in the blood plasma (Cmah) - 2.4-3.0 mg / l.

    After intravenous administration, 0.5 g of vancomycin Cmah is observed at the end of infusion and is about 33 mg / l; After 1 hour and 4 hours after administration, it decreases to 7.3 mg / L and 5.7 mg / L, respectively.

    After intravenous administration of 1 g of vancomycin, its concentration in the blood plasma is doubled. FROMmah is observed immediately after infusion and is from 20 to 50 μg / ml; 12 hours after the infusion the concentration of vancomycin in the plasma varies from 5 to 10 μg / ml. Concentrations in blood plasma with repeated administration are similar concentrations with a single administration.

    Distribution. The volume of distribution 0.2-1.25 l / kg, in children is slightly less than in adults and is 0.53-0.82 l / kg.The connection with plasma proteins is 30-55%. After intravenous administration vancomycin is found in tissues (kidneys, liver, lungs, heart, vessel walls, abscess walls, atrial auricle tissues) and body fluids (pleural, pericardial, ascitic, peritoneal, synovial), as well as in urine in concentrations that inhibit the growth of sensitive microorganisms. Slow penetrates into the cerebrospinal fluid, the penetration rate through the blood-brain barrier increases with inflammation of the meninges. Penetrates through the placental barrier, excreted in breast milk.

    Metabolism. Virtually not metabolized.

    Excretion. The half-life period (T1 / 2) with normal kidney function: adults 4-6 hours (3-9 hours), premature babies - 9.8 hours, newborns - 6.7 hours, children aged 3 years - 2.4 hours , in children aged 7 years - 2.2 hours.

    80-90 % The drug is excreted by the kidneys by glomerular filtration in the first 24 hours in unchanged form. In small amounts (less than 5%) can be excreted with bile. In small amounts, it is excreted in hemodialysis or peritoneal dialysis.

    In adults, the total clearance of vancomycin is 0.7-3.1 ml / s, in children the clearance of vancomycin is higher and reaches the maximum values ​​at the age of 3.9 years (about 3 ml / s).

    Pharmacokinetics in special clinical cases. Impaired renal function slows the excretion of vancomycin, so these patients require a dose adjustment. In patients with a deleted or missing kidney, the mean T1 / 2 is 7.5 days. The total systemic and renal clearance of vancomycin can be reduced in elderly patients as a result of natural slowing of glomerular filtration.

    Indications:

    For intravenous infusion:

    Serious or severe infections caused by microorganisms sensitive to vancomycin, including Staphylococcus spp. (including penicillinase-forming and methicillin-resistant strains), Streptococcus spp. (including strains resistant to penicillin); with an allergic reaction to penicillin; with intolerance or lack of response to treatment with other antibiotics, including penicillins or cephalosporins; in infections caused by microorganisms sensitive to vancomycin, but resistant to other antimicrobial drugs:

    - endocarditis:

    - caused by Streptococcus viridans or Streptococcus bovis (as monotherapy or in combination with aminoglycosides);

    - caused by enterococci, for example Enterococcus faecalis (only in combination with aminoglycosides);

    - early endocarditis caused by Staphylococcus epidermidis or Corynebacterium spp. after valve replacement (in combination with rifampicin, aminoglycosides or both antibiotics);

    - prevention of bacterial endocarditis in patients with hypersensitivity reactions to penicillin antibiotics and heart valve diseases (before dental and surgical procedures);

    - sepsis;

    - infections of the central nervous system (meningitis);

    - infections of the lower respiratory tract (pneumonia, lung abscess);

    - infection of bones and joints (including osteomyelitis);

    - infections of the skin and soft tissues.

    For oral administration:

    - pseudomembranous colitis caused by Clostridium difficile;

    - enterocolitis caused by Staphylococcus aureus.

    Contraindications:

    Hypersensitivity to vancomycin, neuritis of the auditory nerve, lactation period.

    Carefully:

    Hearing impairment (including history), renal failure, patients with allergies to teicoplanin (the possibility of cross-allergy), pregnancy.

    Pregnancy and lactation:

    Use during pregnancy is possible only for "vital" indications in the event that the expected benefit for the mother exceeds the potential risk to the fetus. If it is necessary to use the drug during lactation, breastfeeding should be stopped for the period of treatment with the drug.

    Dosing and Administration:

    Dosage regimens for intravenous drip introduction

    Intravenously (intravenously) is drip. The drug can not be administered intramuscularly or intravenously bolus (struino)!

    Adults and children over 12 years of age, with normal renal function: 0.5 g every 6 hours, or 1 g every 12 hours. Each dose is recommended to enter at a speed of not more than 10 mg / min, the duration of infusion is not less than 60 minutes. The daily dose is 2 g. Age, the presence of obesity may require a change in the usual dose based on the determination of the concentration of vancomycin in the serum.

    Children from 1 month to 12 years: at 10 mg / kg every 6 hours. Each dose is administered for at least 60 minutes. The recommended daily dose is 40 mg / kg.

    Newborns: the initial dose of 15 mg / kg, then in a maintenance dose of 10 mg / kg every 12 hours during the first week of life; beginning from the second week of life a maintenance dose of 10 mg / kg is administered every 8 hours until age 1 month. Each dose should be administered at least 60 minutes, constant monitoring of the concentration of vancomycin in the serum is required.

    The concentration of the prepared solution of vancomycin - not more than 2.5-5 mg / ml. The maximum daily dose for a child should not exceed the daily dose for an adult - 2 g.

    Patients with impaired renal function Individual dose selection is necessary, taking into account the level of serum creatinine. Correction can be carried out by increasing the intervals between administrations, or by reducing the single dose of the drug.

    Correction by increasing the intervals between administrations

    Creatinine clearance (CK) (ml / min)

    Vancomycin Dose

    Interval between doses

    >80

    0.5 g or 1 g

    12h

    80-50

    1 g

    24 h

    50-10

    1 g

    3-7 days

    <10 (anuria)

    1 g

    7-14 days

    In elderly patients clearance of vancomycin below, the volume of distribution is greater, the dose is selected according to the concentration of vancomycin in the serum.

    Have premature babies and elderly patients as a result of reduced renal function, a significant dose reduction may be required. The concentration of vancomycin in the blood plasma should be monitored regularly.

    Correction of a single dose depending on the creatinine clearance

    Creatinine clearance (ml / min)

    Dose of vancomycin (mg / day)

    Creatinine clearance (ml / min)

    Dose of vancomycin (mg / day)

    100

    1545

    50

    770

    90

    1390

    40

    620

    80

    1235

    30

    465

    70

    1080

    20

    310

    60

    925

    10

    155

    When anuria this table can not be used to determine the dose of the drug. For anuria, the initial dose is 15 mg / kg to rapidly create therapeutic concentrations of vancomycin in the serum, for a stable drug concentration, a maintenance dose of 1.9 mg / kg / day.

    Correction by increasing the intervals between administrations

    Patients with severe renal insufficiency are advised to administer maintenance doses of 250-1000 mg once every few days: with KK 10-50 ml / min - 1 g every 3-7 days, with CK <10 ml / min - 1 g every 7-14 days. When anuria a dose of 1 g is recommended every 7-10 days.

    According to the known concentration of creatinine in the serum, calculate the clearance of creatinine according to the formula:

    For men: body weight, kg x (140 - age, years) / 72 x serum creatinine concentration, mg / 100 ml

    For women: the result is multiplied by 0.85.

    Patients on hemodialysis: the initial dose is 20-25 mg / kg, when using membranes with high permeability. Supportive doses are administered based on the residual drug concentration in the blood plasma and adjusted to maintain a residual drug concentration of 15-20 μg / ml.

    Vancomycin is effectively removed by hemodialysis using high-permeability membranes (such as polysulfone), but is poorly eliminated when using membranes with normal permeability.

    Patients with hepatic insufficiency no dose adjustment is required.

    Preparation and administration of a solution for infusion

    Solution for infusion is prepared in two stages.

    First step: the drug is dissolved in water for injection: 0.5 g in 10 ml, 1 g in 20 ml (the concentration of the solution is 50 mg / ml). The solution thus prepared can be stored at room temperature (not higher than 25 ° C) for 24 hours or in a refrigerator (2 to 8 ° C) for 96 hours.

    Second phase: the solutions of vancomycin obtained before the introduction in the first stage are to be further diluted to a concentration of no more than 5 mg / ml before they are injected into a compatible solution for infusions: 0.5 g in 100 ml and 1 g in 200 ml with 0.9% solution of sodium chloride, 5% dextrose solution or Ringer's solution.

    The required dose of vancomycin diluted in this way should be administered by fractional infusion for at least 60 minutes.

    Infusion solutions of the drug based on a 0.9% solution of sodium chloride or 5% dextrose solution can be stored in the refrigerator (2 to 8 ° C) for 14 days without significant loss of activity. Solutions prepared on the basis of Ringer's solution can be stored in the refrigerator for 4 days (96 hours).

    Before administration, the prepared infusion solution should be visually inspected for mechanical impurities and discoloration.

    Dosage regimens for oral administration

    Vancomycin can be used orally to treat pseudomembranous colitis caused by Clostridium difficile due to the use of antibiotics, as well as for the treatment of staphylococcal enterocolitis. Intravenous administration of vancomycin has no advantage in the treatment of these diseases.

    The drug should be used in the following doses: adults 0.5-2 g 3-4 times / day, children 0.04 g / kg 3-4 times / day. The total daily dose should not exceed 2 g. The appropriate dose is prepared in 30 ml of water and given to the patient to drink or injected through the probe. To improve the taste of the solution, ordinary food syrups can be added to it. Duration of treatment is from 7 to 10 days. Vancomycin It is not effective at ingestion in case of other localizations of infections.

    Side effects:

    Violations from the organs of the blood and lymphatic system: leukopenia, reversible neutropenia, transient thrombocytopenia, agranulocytosis, eosinophilia, pancytopenia, anemia.

    Immune system disorders: anaphylactic reactions.

    Heart Disease: heart failure.

    Vascular disorders: decrease in blood pressure, shock, vasculitis.

    Disorders from the gastrointestinal tract: nausea, pseudomembranous colitis.

    Violation of the liver and biliary tract: increased activity of "liver" transaminases.

    Disorders from the side of the organ of vision: transient, prolonged (up to 10 hours) lacrimation.

    Hearing disorders and labyrinthine disturbances: transient or permanent hearing loss, hearing loss, vertigo, tinnitus.

    Disturbances from the respiratory system, organs of the thorax and mediastinum: shortness of breath, respiratory noises.

    Disturbances from the skin and subcutaneous tissues: rash, itching, hives, exfoliative dermatitis, benign (IgA) bubble dermatosis, itchy dermatosis, malignant exudative erythema (Stevens-Johnson syndrome), toxic epidermal necrolysis; drug rash, accompanied by eosinophilia and systemic manifestations (DRESS-syndrome).

    Disorders from the kidneys and urinary tract: renal failure, manifested by increased serum levels of creatinine and urea nitrogen, interstitial nephritis, acute renal failure.

    General disorders and disorders at the site of administration: phlebitis, hyperemia of the upper half of the trunk and face, spasm of muscles of the chest and back, chills, drug fever, pain at the injection site, tissue necrosis at the injection site. During or soon after too rapid infusion of vancomycin, patients may develop anaphylactoid reactions (lowering blood pressure, including shock and cardiac arrest, respiratory noises, shortness of breath, skin rash, itching). Rapid administration of the drug can also cause the syndrome of "red man" (chills, fever, heart palpitations, hyperemia of the upper body and face, spasm of the muscles of the chest and back). After the infusion has stopped, the reactions usually last for 20 minutes, but sometimes can last up to several hours. In a number of patients who received vancomycin, symptoms of ototoxicity were observed. They can be transitory and have a permanent character. The majority of such cases were observed in patients receiving high doses of vancomycin, with hearing loss and renal insufficiency in the anamnesis, or in patients receiving simultaneous treatment with other drugs with the possible development of ototoxicity, for example, aminoglycosides.

    Overdose:

    Symptoms: intensification of the expression of dose-dependent side effects from the urinary and sensory systems.

    Treatment: there is no specific antidote. It is recommended to cancel the drug or reduce the dose. Conduct symptomatic therapy aimed at maintaining glomerular filtration. It is recommended to administer the liquid and monitor the plasma concentrations of vancomycin.

    Vancomycin is poorly removed by dialysis. There is evidence that hemofiltration and hemoperfusion through polysulfone ion exchange resin lead to an increase in vancomycin clearance.

    Interaction:

    With the simultaneous use of vancomycin and anesthetics, erythema and anaphylactoid reactions (including a decrease in blood pressure, rash, hives and itching) were noted. The administration of vancomycin in the form of a 60-minute infusion prior to induction of anesthesia may reduce the likelihood the occurrence of these reactions. If vancomycin injected during or immediately after surgery, while using muscle relaxants (for example, suxamethonium iodide), their effects (neuromuscular blockade) can be strengthened and prolonged.

    With simultaneous and / or consistent systemic or local application of other potentially ototoxic and / or nephrotoxic drugs (aminoglycosides, amphotericin B, aminosalicylic acid or other salicylates, bacitracin, capreomycin, carmustine, paromomycin, ciclosporin, "loop" diuretics, polymyxin AT, cisplatin, ethacrynic acid) requires careful monitoring of the possible development of these symptoms.

    Kolestyramine reduces the effectiveness of vancomycin (for oral administration). Antihistamines, meclozine, phenothiazines, thioxaptenes can mask the symptoms of ototoxic action of vancomycin (tinnitus, vertigo). Pharmaceutical interaction. The solution of vancomycin has a low pH, which can cause physical or chemical instability when mixed with other solutions. Avoid mixing with alkaline solutions.

    It is not recommended to mix or simultaneously use a solution of vancomycin with chloramphenicol, glucocorticoids, aminophylline and phenobarbital.

    Solutions of vancomycin and beta-lactam antibiotics are pharmaceutically incompatible with mixing.The probability of precipitation increases with increasing concentration of vancomycin.

    It is necessary to thoroughly wash the IV in the system between the applications of these antibiotics. It is recommended to reduce the concentration of vancomycin solution to 5 mg / ml or less.

    Special instructions:

    Rapid administration (eg, within a few minutes) can be accompanied by a marked decrease in blood pressure and, in rare cases, cardiac arrest. A solution of vancomycin for infusions should be administered for at least 60 minutes to avoid adverse reactions associated with infusion.

    Caution should be applied vancomycin in patients with renal insufficiency (doses of vancomycin should be individually determined, it is recommended to monitor the concentration of vancomycin in the blood plasma for renal failure in patients older than 60 years), since at high, long-term concentrations of the drug in the blood may increase the risk of manifestations of the toxic effect of the drug; the maximum concentration should not exceed 40 μg / ml, the minimum concentration should be 10 μg / ml, concentrations above 80 μg / ml are considered toxic.

    Vancomycin should be administered with caution to allergic patients teicoplanin, since cases of cross-allergy have been reported.

    With prolonged use of vancomycin, an audiogram, a control of the peripheral blood picture, kidney function (general urine analysis, creatinine and urea nitrogen) is necessary.

    Vancomycin is an irritant, so the diffusion of the dissolved drug through the vascular wall can cause necrosis of adjacent tissues. There were thrombophlebitis, although the likelihood of their development can be reduced by slow introduction of dilute solutions (with a concentration of 2.5-5 mg / ml) and alternation of injection sites.

    Application in pediatrics. When appointing newborns (including premature), it is recommended to control the concentration of vancomycin in the blood plasma.

    Vancomycin is poorly absorbed after oral administration, therefore it can be administered orally only for the treatment of staphylococcal enterocolitis and pseudomembranous colitis caused by Clostridium difficile.

    Effect on the ability to drive transp. cf. and fur:

    The influence of vancomycin on the management of vehicles and the employment of other potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions have not been studied.However, it should be taken into account that the use of vancomycin can be accompanied by such undesirable phenomena as dizziness associated with a drop in blood pressure. Patients experiencing dizziness should refrain from driving vehicles and working with potentially dangerous mechanisms.

    Form release / dosage:

    Lyophilizate for solution for infusion and oral administration 0.5 g, 1.0 g.

    Packaging:

    0.5 g, 1.0 g of active ingredient in bottles with the capacity of 10 ml, 20 ml of colorless transparent glass, hermetically sealed with rubber stoppers, crimped with aluminum caps or combined.

    1 bottle with instructions for use in a pack of cardboard.

    10 bottles with instructions for use in a cardboard box.

    For hospitals:

    - 50 bottles with an equal number of instructions for use in a cardboard box;

    - from 1 to 50 bottles with an equal number of instructions for use in a cardboard box.

    Complete with a solvent.

    Water for injection 5 ml or 10 ml in ampoules of glass.

    For a dose of 0.5 g: 1 vial and 1 ampoule 10 ml or 2 ampoules of 5 ml in a contiguous cell package (NLC) from a polyvinylchloride film with instructions for use in a pack of cardboard.

    For a dose of 1.0 g: 1 bottle and 2 ampoules of 10 ml each in the KNU with instructions for use in a pack of cardboard.

    In the pack put a knife to open the ampoules or a scarifier ampoule. When using ampoules with notches, rings or break points, the ampoule opener opener or ampoule scarifier is allowed not to be inserted.

    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

    Shelf life:2 years. Do not use after the expiration date.
    Terms of leave from pharmacies:On prescription
    Registration number:LP-004821
    Date of registration:24.04.2018
    Expiration Date:24.04.2023
    The owner of the registration certificate:KRASFARMA, JSC KRASFARMA, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp05.06.2018
    Illustrated instructions
      Instructions
      Up